April 15, 2026 Adragos Pharma Kawagoe K.K. (Headquarters: Kawagoe, Saitama; Representative Director and President: Masanori Kurogome) has signed a basic agreement with Towa Pharmaceutical Co., Ltd. (Headquarters: Kadoma, Osaka; President and CEO: Itsuro Yoshida) to establish a strategic collaboration aimed at ensuring the stable supply of off-patent pharmaceuticals. Under the agreement, Adragos Pharma will promote contract manufacturing utilizing the Kawagoe plant and secureproductioncapacity to supply up to 1.5 billion tablets per year for Towa Pharmaceutical on a planned basis.
As the importance of ensuring a stable supply of off-patent medicines continues to grow in Japan, Adragos Pharma believes that pharmaceutical contract manufac-turers have an important role to play in supporting a more sustainable supply structure. Through this collaboration with Towa Pharmaceutical, the Company aims to contribute to the broader national effort to strengthen domestic manufacturing capacity, production resilience, and long-term supply stability.
Pictured: Dr. Andreas Raabe, Founder and CEO of Adragos Pharma, and Mr. Itsuro Yoshida, President and CEO of Towa Pharmaceutical Co., Ltd.
Production framework
Leveraging this partnership, Adragos Pharma will accelerate capital investment at the Kawagoe plant and expand annual solid-dosage capacity from the current 1.0 billion tablets to 2.5 billion tablets in stages. Of this total, capacity of approximately 1.5 billion tablets will be allocated to Towa Pharmaceutical. By sharing demand and supply forecasts, the two companies will work to ensure a stable supply of medicines.
Comments
· Masanori Kurogome, Representative Director, Adragos Pharma Kawagoe K. K. “Our collaboration with Towa Pharmaceutical represents an important partnership in supporting the stable supply of off-patent medicines. Through capital investment at our Kawagoe plant, we will further strengthen our production and quality assurance systems and, with qualityas our highest priority, contribute to a more stable domestic supply of medicines. At the same time, this partnership will support the continued en-hancement of our capabilities as a CDMO and our sustainable growth.”
· Dr. Andreas Raabe, Founder and CEO, Adragos Pharma “This agreement reflects the important role that specialized manufacturing partners can play in supporting the stable supply of medicines. By investing in our Kawagoe site and working closely with Towa Pharmaceutical, we aim to contribute to a stronger and more resilient supply framework for off-patent medicines in Japan.”
About Adragos Pharma
Adragos Pharma is a fast-growing global CDMO headquartered in Munich, Germany. Leveraging a network of seven manufacturing sites across Europe and Japan, we provide end-to-end pharmaceutical services from development through commercial manufacturing to support our clients. With advanced technical exper-tise and a customer-centric approach, we deliver high-quality, reliable solutions that meet the evolving needs of the pharmaceutical industry.
